1. In this prospective within-patient trial, metomidate (MTO) positron emission tomography-computed tomography was non-inferior to adrenal vein sampling in identifying ...
1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There were fewer treatment-related and serious adverse ...
Click to read this study in the Journal of Clinical Oncology.
1. For the detection of pelvic nodal metastases in men with intermediate-to high-risk prostate cancer, using the 68Ga-PSMA-11 PET scan, the ...
1. For the detection of pelvic nodal metastases in men with intermediate-to high-risk prostate cancer, using the 68Ga-PSMA-11 PET scan, ...
1. flortaucipir positron emission tomography (“Tau PET”) imaging predicted changes in mental status with a stronger effect size than standard ...
1. 3-year event-free survival rates were significantly greater in the 18F-fluciclovine-PET group compared to conventional imaging. 2. Adverse reactions and ...
